Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carmen Ramirez-Boyd

Nurse Practitioner Jacksonville, FL Nurse Practitioner

NPI 1730345943 CMS profile 11014121

4727 Sunbeam Rd, Jacksonville, FL 32257

Open in the dashboard

General payments

$13,412

574 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Ramirez-Boyd of Jacksonville, FL is reported in the CMS Open Payments database as having received $13,412 across 574 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,255 114
2024 General $2,779 114
2023 General $3,153 146
2022 General $3,242 123
2021 General $1,982 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Ramirez-Boyd
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Carmen Ramirez-Boyd were reported at $2,255. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Carmen Ramirez-Boyd Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,982 $135 $40–$426 $132
2022 $3,242 $152 $48–$470 $149
2023 $3,153 $166 $54–$529 $160
2024 $2,779 $173 $55–$556 $164
2025 $2,255 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,204 72 payments
  2. LEO Pharma Inc. $1,291 80 payments
  3. Janssen Biotech, Inc. $1,154 57 payments
  4. Sun Pharmaceutical Industries Inc. $1,082 36 payments
  5. E.R. Squibb & Sons, L.L.C. $735 21 payments
  6. Galderma Laboratories, L.P. $720 40 payments
  7. Novartis Pharmaceuticals Corporation $692 42 payments
  8. Incyte Corporation $614 21 payments
  9. UCB, Inc. $611 31 payments
  10. Regeneron Healthcare Solutions, Inc. $526 21 payments
  11. Other $3,782 153 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,818 567 payments
  2. Education $564 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30 1 payment
Products named General payments · program years 2021–2025
  1. ADBRY $1,231 77 payments
  2. RINVOQ $1,208 29 payments
  3. TREMFYA $1,170 45 payments
  4. SKYRIZI $854 28 payments
  5. SOTYKTU $707 20 payments
  6. OPZELURA $614 21 payments
  7. ILUMYA $484 20 payments
  8. DUPIXENT $383 16 payments
  9. Cimzia $371 22 payments
  10. Winlevi $283 10 payments
  11. Other $6,839 359 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

476

Median for Nurse Practitioner: 389

Drug cost

$7,698

Median for Nurse Practitioner: $21,885

Branded share of claims

2.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 122 $1,670
Clobetasol Propionate Generic 58 $1,571
Metronidazole Generic 12 $913
Triamcinolone Acetonide Generic 102 $761
Minocycline Hcl Generic 42 $739
Doxycycline Hyclate Generic 23 $439
Valacyclovir Valacyclovir Hcl Brand 11 $390
Clindamycin Phosphate Generic 12 $335
Hydroxyzine Hcl Generic 17 $312
Nystatin Generic 12 $225

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$114,802

Of which drugs: $3,711

Medicare patients

406

Average age 74

Services billed

4,898

255 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Ischemic heart disease 30%
Diabetes 24%
Depression 21%
Chronic kidney disease 18%
Osteoporosis 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 118 $91

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $344
$344 — —
TREMFYA
  • Janssen Biotech, Inc. $286
$286 — —
ADBRY
  • LEO Pharma Inc. $246
$246 — —
SKYRIZI
  • AbbVie, Inc. $185
$185 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $176
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

574 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record